Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Reformulated Oxycontin | Contract Pharma

What are you searching for?

Sign in

FDA Approves Reformulated Oxycontin

The FDA has approved Purdue Pharma's NDA for a reformulation of OxyContin (oxycodone HCl controlled-release) Tablets.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The FDA has approved Purdue Pharma’s NDA for a reformulation of OxyContin (oxycodone HCl controlled-release) Tablets. The reformulated tablet meets the FDA’s criteria for bioequivalence to the original formulation and is an effort to make the tablet more difficult to manipulate for the purpose of intentional misuse and abuse.

OxyContin is a CII controlled substance with all the risks of Schedule II opioids, in particular, that the drug has a high potential for abuse. The reformulated tablets are designed to be harder to crush and more difficult to dissolve, as opposed to current tablets that can be easily crushed or chewed, allowing all of the drug’s active ingredient to immediately be released.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters